AbbVie to Divest Allergan’s Brazikumab and Zenpep (pancrelipase) to Gain the US FTC and EC’s Approval on Pending Allergan Acquisition

 AbbVie to Divest Allergan’s Brazikumab and Zenpep (pancrelipase) to Gain the US FTC and EC’s Approval on Pending Allergan Acquisition

AbbVie to Divest Allergan’s Brazikumab and Zenpep (pancrelipase) to Gain the US FTC and EC’s Approval on Pending Allergan Acquisition

Shots:

  • Allergan will divest its brazikumab to AstraZeneca including its global development and commercialization rights while Nestle to acquire complete ownership of Zenpep and will be acquiring Viokace as a part of the same transaction
  • The divestiture of two therapies is in conjunction with the ongoing US FTC’s and EC’s approval. The transactions are expected to be completed simultaneously with the pending acquisition whereas AbbVie is expected to complete its pending transaction in Q1’20
  • Brazikumab is a mAb targeting IL23 receptor, currently being evaluated in P-IIb/III study for CD & P-IIb for UC while Zenpep is prescription therapy for patients with for exocrine pancreatic insufficiency due to CF and other conditions

Click here ­to­ read full press release/ article | Ref: AbbVie | Image: Livemint

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post